VBI Vaccines Inc. (NASDAQ:VBIV)’s quarterly earnings will be published on May, 7., according to RTT. The earnings per share diference is $0.04 or 21.05 % up from last years number. Previous year: $-0.19; Analysts forcast: $-0.15. Analysts at Wall Street see VBI Vaccines Inc.’s -46.43 % EPS growth compared to $-0.28 earnings per share for previous quarter. Lastly it traded at $2.07.It’s downtrending since April 15, 2018 and is 48.69% up. VBIV underperformed by 53.06% the S&P 500.

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally.The firm is worth $202.16 million. The firm offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.Last it reported negative earnings. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology.

For more VBI Vaccines Inc. (NASDAQ:VBIV) news announced briefly go to: Nasdaq.com, Globenewswire.com, Globenewswire.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop – Nasdaq” announced on April 03, 2019, “VBI Vaccines Announces Pricing of $37.5 Million Public Offering – GlobeNewswire” on December 13, 2018, “VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine – GlobeNewswire” with a publish date: October 16, 2018, “VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate – GlobeNewswire” and the last “VBI Vaccines Announces Proposed Public Offering of Common Shares – GlobeNewswire” with publication date: December 12, 2018.